Log in

OTCMKTS:USRM - US Stem Cell Stock Price, Forecast & News

$0.0055
0.00 (0.00 %)
(As of 03/29/2020 05:57 AM ET)
Today's Range
$0.00
Now: $0.01
$0.01
50-Day Range
$0.00
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.03
Volume2.27 million shs
Average Volume791,477 shs
Market Capitalization$2.34 million
P/E RatioN/A
Dividend YieldN/A
Beta5.29
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.
Read More

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:USRM
Previous SymbolNASDAQ:BHRT
CUSIPN/A
CIKN/A
Phone954-835-1500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.70 million
Book Value($0.02) per share

Profitability

Net Income$-2,160,000.00

Miscellaneous

Employees10
Market Cap$2.34 million
Next Earnings Date4/1/2020 (Estimated)
OptionableNot Optionable

Receive USRM News and Ratings via Email

Sign-up to receive the latest news and ratings for USRM and its competitors with MarketBeat's FREE daily newsletter.


US Stem Cell (OTCMKTS:USRM) Frequently Asked Questions

How has US Stem Cell's stock been impacted by COVID-19 (Coronavirus)?

US Stem Cell's stock was trading at $0.0061 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, USRM stock has decreased by 9.8% and is now trading at $0.0055. View which stocks have been mosted impacted by Coronavirus.

When is US Stem Cell's next earnings date?

US Stem Cell is scheduled to release its next quarterly earnings announcement on Wednesday, April 1st 2020. View our earnings forecast for US Stem Cell.

How were US Stem Cell's earnings last quarter?

US Stem Cell Inc (OTCMKTS:USRM) released its quarterly earnings results on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The company had revenue of $1.30 million for the quarter. View US Stem Cell's earnings history.

Has US Stem Cell been receiving favorable news coverage?

News articles about USRM stock have trended somewhat positive on Sunday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. US Stem Cell earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutUS Stem Cell.

Who are some of US Stem Cell's key competitors?

What other stocks do shareholders of US Stem Cell own?

Who are US Stem Cell's key executives?

US Stem Cell's management team includes the following people:
  • Mr. Michael Tomas, CEO, Pres, CFO & Director (Age 53)
  • Dr. Kristin C. Comella Ph.D., Chief Science Officer & Director (Age 42)
  • Dr. Colleen Robb, Sr. Compliance Officer
  • Mr. Phil Posa, Sr. VP of U.S. & International Sales
  • Ms. Evelyn Flores, Corp. Controller

What is US Stem Cell's stock symbol?

US Stem Cell trades on the OTCMKTS under the ticker symbol "USRM."

How do I buy shares of US Stem Cell?

Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is US Stem Cell's stock price today?

One share of USRM stock can currently be purchased for approximately $0.01.

How big of a company is US Stem Cell?

US Stem Cell has a market capitalization of $2.34 million and generates $6.70 million in revenue each year. US Stem Cell employs 10 workers across the globe. View additional information about US Stem Cell.

What is US Stem Cell's official website?

The official website for US Stem Cell is http://www.us-stemcell.com/.

How can I contact US Stem Cell?

US Stem Cell's mailing address is 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325. The company can be reached via phone at 954-835-1500 or via email at [email protected]


MarketBeat Community Rating for US Stem Cell (OTCMKTS USRM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about US Stem Cell and other stocks. Vote "Outperform" if you believe USRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe USRM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Growth and Income Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel